TransCode Therapeutics Inc (NASDAQ:RNAZ)’s traded shares stood at 2.66 million during the last session, with the company’s beta value hitting 0.64. At the close of trading, the stock’s price was $0.67, to imply an increase of 10.33% or $0.06 in intraday trading. The RNAZ share’s 52-week high remains $20.69, putting it -2988.06% down since that peak but still an impressive 67.16% since price per share fell to its 52-week low of $0.22. The company has a valuation of $11.62M, with an average of 1.47 million shares in intraday trading volume over the past 10 days and average of 2.18 million shares over the past 3 months.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
After registering a 10.33% upside in the last session, TransCode Therapeutics Inc (RNAZ) has traded red over the past five days. The 5-day price performance for the stock is -0.90%, and 61.43% over 30 days. With these gigs, the year-to-date price performance is -89.79%. Short interest in TransCode Therapeutics Inc (NASDAQ:RNAZ) saw shorts transact 1.38 million shares and set a 0.45 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Looking at statistics comparing TransCode Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. TransCode Therapeutics Inc (RNAZ) shares are 52.99% up over the last 6 months, with its year-to-date growth rate higher than industry average at 98.01% against 17.50%. Revenue is forecast to grow 99.30% this quarter before jumping 99.20% for the next one.
Revenue forecast for the current quarter as set by 1 analysts is 300k. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 300k.
RNAZ Dividends
TransCode Therapeutics Inc has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
TransCode Therapeutics Inc insiders hold 0.03% of total outstanding shares, with institutional holders owning 11.46% of the shares at 11.47% float percentage. In total, 11.46% institutions holds shares in the company.
